Compare CPBI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPBI | LUNG |
|---|---|---|
| Founded | 2023 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 97.1M |
| IPO Year | 2023 | 2020 |
| Metric | CPBI | LUNG |
|---|---|---|
| Price | $20.00 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | 4.8K | ★ 262.1K |
| Earning Date | 11-18-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.38 | 7.64 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $0.06 |
| Revenue Next Year | N/A | $8.58 |
| P/E Ratio | $51.26 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $15.56 | $1.13 |
| 52 Week High | $21.83 | $2.89 |
| Indicator | CPBI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 41.98 |
| Support Level | $19.73 | $1.20 |
| Resistance Level | $20.74 | $2.12 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 43.10 | 27.19 |
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.